275 related articles for article (PubMed ID: 27586252)
1. Terlipressin, a vasoactive prodrug recommended in hepatorenal syndrome, is an agonist of human V1, V2 and V1B receptors: Implications for its safety profile.
Colson PH; Virsolvy A; Gaudard P; Charrabi A; Corbani M; Manière MJ; Richard S; Guillon G
Pharmacol Res; 2016 Nov; 113(Pt A):257-264. PubMed ID: 27586252
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist.
Castillo GM; Yao Y; Guerra RE; Jiang H; Nishimoto-Ashfield A; Lyubimov AV; Alfaro JF; Striker KA; Buynov N; Schwabl P; Bolotin EM
Biomed Pharmacother; 2024 Feb; 171():116068. PubMed ID: 38176129
[TBL] [Abstract][Full Text] [Related]
3. In vitro binding and receptor-mediated activity of terlipressin at vasopressin receptors V
Jamil K; Pappas SC; Devarakonda KR
J Exp Pharmacol; 2018; 10():1-7. PubMed ID: 29302194
[TBL] [Abstract][Full Text] [Related]
4. Effects of the vasopressin agonist terlipressin on plasma cAMP and ENaC excretion in the urine in patients with cirrhosis and water retention.
Krag A; Pedersen EB; Møller S; Bendtsen F
Scand J Clin Lab Invest; 2011 Apr; 71(2):112-6. PubMed ID: 21080762
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and physiological characterization of d[Leu4, Lys8]vasopressin, the first V1b-selective agonist for rat vasopressin/oxytocin receptors.
Pena A; Murat B; Trueba M; Ventura MA; Bertrand G; Cheng LL; Stoev S; Szeto HH; Wo N; Brossard G; Serradeil-Le Gal C; Manning M; Guillon G
Endocrinology; 2007 Sep; 148(9):4136-46. PubMed ID: 17495006
[TBL] [Abstract][Full Text] [Related]
6. 1-desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor.
Saito M; Tahara A; Sugimoto T
Biochem Pharmacol; 1997 Jun; 53(11):1711-7. PubMed ID: 9264324
[TBL] [Abstract][Full Text] [Related]
7. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.
Thibonnier M; Auzan C; Madhun Z; Wilkins P; Berti-Mattera L; Clauser E
J Biol Chem; 1994 Feb; 269(5):3304-10. PubMed ID: 8106369
[TBL] [Abstract][Full Text] [Related]
8. Terlipressin, a provasopressin drug exhibits direct vasoconstrictor properties: consequences on heart perfusion and performance.
Ryckwaert F; Virsolvy A; Fort A; Murat B; Richard S; Guillon G; Colson PH
Crit Care Med; 2009 Mar; 37(3):876-81. PubMed ID: 19237891
[TBL] [Abstract][Full Text] [Related]
9. [1-deamino-4-cyclohexylalanine] arginine vasopressin: a potent and specific agonist for vasopressin V1b receptors.
Derick S; Cheng LL; Voirol MJ; Stoev S; Giacomini M; Wo NC; Szeto HH; Ben Mimoun M; Andres M; Gaillard RC; Guillon G; Manning M
Endocrinology; 2002 Dec; 143(12):4655-64. PubMed ID: 12446593
[TBL] [Abstract][Full Text] [Related]
10. Effects of terlipressin on the aquaretic system: evidence of antidiuretic effects.
Krag A; Bendtsen F; Pedersen EB; Holstein-Rathlou NH; Møller S
Am J Physiol Renal Physiol; 2008 Nov; 295(5):F1295-300. PubMed ID: 18753292
[TBL] [Abstract][Full Text] [Related]
11. Subcellular localization and internalization of the vasopressin V1B receptor.
Kashiwazaki A; Fujiwara Y; Tsuchiya H; Sakai N; Shibata K; Koshimizu TA
Eur J Pharmacol; 2015 Oct; 765():291-9. PubMed ID: 26318147
[TBL] [Abstract][Full Text] [Related]
12. Vasopressin analogues and V1a receptor agonists in septic shock.
Maybauer MO; Maybauer DM
Inflamm Res; 2011 May; 60(5):425-7. PubMed ID: 21312051
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
14. A vasopressin analog that binds but does not activate V1 or V2 vasopressin receptors is not internalized into cells that express V1 or V2 receptors.
Lutz W; Londowski JM; Sanders M; Salisbury J; Kumar R
J Biol Chem; 1992 Jan; 267(2):1109-15. PubMed ID: 1309761
[TBL] [Abstract][Full Text] [Related]
15. Similarities between hamster pancreatic islet beta (HIT) cell vasopressin receptors and V1b receptors.
Richardson SB; Laya T; VanOoy M
J Endocrinol; 1995 Oct; 147(1):59-65. PubMed ID: 7490538
[TBL] [Abstract][Full Text] [Related]
16. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
[TBL] [Abstract][Full Text] [Related]
17. Stimulation of V1a receptor increases renal uric acid clearance via urate transporters: insight into pathogenesis of hypouricemia in SIADH.
Taniguchi K; Tamura Y; Kumagai T; Shibata S; Uchida S
Clin Exp Nephrol; 2016 Dec; 20(6):845-852. PubMed ID: 26935049
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome.
Krag A; Borup T; Møller S; Bendtsen F
Adv Ther; 2008 Nov; 25(11):1105-40. PubMed ID: 19018483
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterization of FE 201874, the first selective high affinity rat V1A vasopressin receptor agonist.
Marir R; Virsolvy A; Wisniewski K; Mion J; Haddou D; Galibert E; Meraihi Z; Desarménien MG; Guillon G
Br J Pharmacol; 2013 Sep; 170(2):278-92. PubMed ID: 23725319
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
